New weight-loss drug sails through all-important Phase III trial
A novel weight loss drug in the same class as semaglutide has successfully met its targets in its largest clinical trial yet, with nearly 90% of participants losing at least 5% of their body weight. The results strengthen its case for US Food and Drug Administration approval. Continue Reading Category: Obesity, Illnesses and conditions, Body […]
Lilly expects orforglipron obesity results in third quarter – Reuters
Lilly expects orforglipron obesity results in third quarter Reuters Lilly’s oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine Eli Lilly Lilly Obesity Pill to Rival Shots Holds Up to Scrutiny in Trial Bloomberg Eli Lilly’s phase 1 amylin […]
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial
Publication date: Available online 20 June 2025 Source: The Lancet Author(s): Agnes Gasiorek, Arne Heydorn, Sanaz Gabery, Julie B Hjerpsted, Katrine Kirkeby, Thomas Kruse, Signe B Petersen, Søren Toubro, Andreas Vegge, Cassandra Key
GLP-1 and amylin receptor multiagonism with amycretin for obesity management
Publication date: Available online 20 June 2025 Source: The Lancet Author(s): Bernard Khoo, Tricia M-M Tan
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
Publication date: Available online 20 June 2025 Source: The Lancet Author(s): Kirsten Dahl, Søren Toubro, Sohan Dey, Ruben Duque do Vale, Anne Flint, Agnes Gasiorek, Arne Heydorn, Ania M Jastreboff, Cassandra Key, Signe Beck Petersen, Andreas Vegge, Kasper Adelborg
Novo is not dead yet! Novo Nordisk’s experimental drug results in up to 24% weight loss
June 20 (Reuters) – Novo Nordisk (NOVOb.CO) On Friday said full results from early-stage trials show that its experimental drug, amycretin, helped overweight and obese adults lose up to 24% of their weight as the Danish company readies for late-stage studies to start next year. The company said side effects of the drug, tested as both a […]
Eli Lilly’s Obesity Pill Appears to Work as Well as Injected GLP-1s – wired.com
Eli Lilly’s Obesity Pill Appears to Work as Well as Injected GLP-1s wired.com Lilly’s oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine Eli Lilly Lilly expects orforglipron obesity results in third quarter Reuters Lilly Obesity Pill to Rival […]
Novo Nordisk: Ignored GLP-1 Leader Is Now A Deep Value Play
Post Content
Novo Nordisk: Ignored GLP-1 Leader Is Now A Deep Value Play
Diabetes drug cuts migraines in half by targeting brain pressure
A common diabetes drug may be the next big thing for migraine relief. In a clinical study, obese patients with chronic migraines who took liraglutide, a GLP-1 receptor agonist, experienced over 50% fewer headache days and significantly improved daily functioning without meaningful weight loss. Researchers believe the drug s ability to lower brain fluid pressure […]